AGREEMENTAgreement • May 11th, 2004 • Venrock Associates • Pharmaceutical preparations
Contract Type FiledMay 11th, 2004 Company IndustryPursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D/A is being filed on behalf of each of the undersigned.
AMENDMENT NO. 1 TO COMMON STOCK AND WARRANT PURCHASE AGREEMENTCommon Stock and Warrant Purchase Agreement • May 11th, 2004 • Venrock Associates • Pharmaceutical preparations • Delaware
Contract Type FiledMay 11th, 2004 Company Industry JurisdictionThis Amendment (the “Amendment”) to that certain Common Stock and Warrant Purchase Agreement, dated as of February 11, 2003, by and among Sirna Therapeutics, Inc. (formerly known as Ribozyme Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), and the investors listed on Exhibit A thereto (the “Agreement”), is made as of May 10, 2004, by and among the Company and the parties to the Agreement listed on the signature pages hereto, each of which is herein referred to as an “Investor.” Capitalized terms not defined herein shall have the meanings ascribed to them in the Agreement.
TERMINATION AGREEMENTTermination Agreement • May 11th, 2004 • Venrock Associates • Pharmaceutical preparations • Delaware
Contract Type FiledMay 11th, 2004 Company Industry JurisdictionThis TERMINATION AGREEMENT (the “Agreement”) is made this 10th day of May, 2004, by and among DLJ Capital Corporation, Sprout Capital IX, L.P., Sprout Entrepreneurs’ Fund, L.P., Sprout IX Plan Investors, L.P., Venrock Associates, Venrock Associates III, L.P., Venrock Entrepreneurs Fund III, L.P., Oxford Bioscience Partners IV L.P. and mRNA Fund II, L.P. (each an Investor, and, collectively, the “Investors”).